This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

On Demand Treatment of Reflux Disease

This study has been completed.
Ferrosan AS
Information provided by:
Norwegian University of Science and Technology Identifier:
First received: September 15, 2005
Last updated: August 8, 2011
Last verified: September 2005
A comparison of the effect of on demand treatment with a pectin-containing natural product (Aflurax) with that esomeprazole (Nexium)

Condition Intervention Phase
Gastroesophageal Reflux Drug: Aflurax Drug: esomeprazole Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Aflurax Versus Nexium Given on Demand to Patients With Gastro-esophageal Reflux Disease.

Resource links provided by NLM:

Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Symptomatic relief

Secondary Outcome Measures:
  • Overall satisfaction

Enrollment: 82
Study Start Date: August 2002
Study Completion Date: December 2004
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aflurax
pectin-containing natural product
Drug: Aflurax
Other Name: Pectin-containing nature product
Active Comparator: esomeprazole (Nexium)
esomeprazole (Nexium)
Drug: esomeprazole
Other Name: Nexium

Detailed Description:
A randomized, controlled, open trial comparing the symptomatic effect of a pectin-containing product (Aflurax) with that of esomeprazole (Nexium 20 mg) given on-demand for 6 weeks.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Mild and moderate reflux symptoms Age > 17 years Informed consent -

Exclusion Criteria:

Other conditions that might explain the symptoms Abuse of drugs or alcohol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00184522

Gjøvik Specialist Centre
Gjøvik, Norway, 2800
Sykehuset Innlandet HF, Gjøvik
Gjøvik, Norway, 2819
Sykehuset Innlandet HF, Hamar
Hamar, Norway
Sykehuset Innlandet HF, Kongsvinger
Kongsvinger, Norway
Sykehuset Innlandet HF, Lillehammer
Lillehammer, Norway
Helse Nord-Møre og Romsdal
Molde, Norway
Mosjøen sykehus
Mosjøen, Norway
Helse Nord-Trøndelag
Namsos, Norway
Sykehuset Innlandet HF, Tynset
Tynset, Norway
Sponsors and Collaborators
Norwegian University of Science and Technology
Ferrosan AS
Study Chair: Per G Farup, PhD Norwegian University of Science and Technology
  More Information

Responsible Party: Professor MD Per Farup, Norwegian University of science and technology Identifier: NCT00184522     History of Changes
Other Study ID Numbers: SLV 02-01973
Study First Received: September 15, 2005
Last Updated: August 8, 2011

Keywords provided by Norwegian University of Science and Technology:
Gastroesophageal Reflux
Drug treatment

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017